Chronic Adverse Effects From Anti-PD-1 Immunotherapies Common
About 43 percent of patients who receive anti-PD1 therapy for advanced melanoma have chronic immune-related adverse effects
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.